These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24507058)

  • 21. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications.
    Barrera-Pulido L; Alamo-Martínez JM; Marín-Gómez LM; Suárez-Artacho G; Bernal-Bellido C; Domínguez-Usero D; Tallón-Aguilar L; Pareja-Ciuró F; Sousa-Martín JM; García-González I; Gómez-Bravo MA
    Transplant Proc; 2009; 41(6):2192-4. PubMed ID: 19715870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
    Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
    Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study.
    Manger B; Hiepe F; Schneider M; Worm M; Wimmer P; Paulus EM; Schwarting A
    Clin Exp Gastroenterol; 2015; 8():205-13. PubMed ID: 26229499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies.
    Pietruck F; Abbud-Filho M; Vathsala A; Massari PU; Po-Huang L; Nashan B
    Transplant Proc; 2007; 39(1):103-8. PubMed ID: 17275484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Reinke P; Budde K; Hugo C; Petersen P; Schnuelle P; Fricke L; Scholz D; Sperschneider H; Bahner U; Kramer S; Fischer W; Arns W
    Transplant Proc; 2011 Jun; 43(5):1641-6. PubMed ID: 21693250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
    Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
    Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
    Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications.
    Miras M; Carballo F; Egea J; Martínez C; Alvarez-López MR; Sánchez-Bueno F; Parrilla P
    Transplant Proc; 2007 Sep; 39(7):2314-7. PubMed ID: 17889175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of mycophenolate sodium in stable renal transplant recipients in Spain: preliminary results of the MIDATA study.
    Sánchez-Fructuoso A; Ruiz JC; Rengel M; Andrés A; Morales JM; Beneyto I; Guirado LI; Cantarell C;
    Transplant Proc; 2009; 41(6):2309-12. PubMed ID: 19715904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
    Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N;
    J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
    Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
    Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
    Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
    Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of tolerance and safety of conversion from mycophenolate mofetil to enteric-coated mycophenolic acid in renal transplant recipients.
    Qiao LW; Qu QS; Jiang X
    J Biol Regul Homeost Agents; 2017; 31(1):141-146. PubMed ID: 28337883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M; Girón F; Hernández E; Juarez F; Liendo C; Novoa P; Toledo M;
    Transplant Proc; 2004; 36(6):1647-9. PubMed ID: 15350440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.
    Martinez-Mier G; Salazar-Ramirez A
    Transplant Proc; 2016 Mar; 48(2):588-95. PubMed ID: 27110009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children.
    Pape L; Ahlenstiel T; Kreuzer M; Ehrich JH
    Pediatr Transplant; 2008 Sep; 12(6):640-2. PubMed ID: 18798359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
    Qin Y; Zhang F; Shen B; Liu Y; Qiu J; Guo Y; Fan Y
    Int J Clin Pract Suppl; 2014 Apr; (181):17-22. PubMed ID: 24673715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.